Answers are grounded in this paper and cite their sources.
Current diabetic retinopathy management relies primarily on contemporaneous severity grading and does not directly quantify the short-term risk of vision-threatening complications. We developed and internally evaluated image-based artificial intelligence models for one-year prediction of diabetic retinopathy severity, proliferative diabetic retinopathy (PDR) and center-involved diabetic macular edema (ci-DME) using retinal imaging acquired during routine care.The prospective multicenter EviRed cohort included 3,183 patients with diabetes, 8,520 visits and 16,509 eye-level observations collected across 14 French hospitals. Device-specific ensembles were developed for ultra-widefield color fundus photography (CLARUS500 and OPTOS) and OCT angiography (CIRRUS5000 and PLEX Elite9000). Predictions from individual images and both eyes were aggregated at the patient-visit level. Participants were partitioned at the patient level into adevelopment set (65\%) and a held-out test set (35\%).For prediction of diabetic retinopathy severity at the subsequent annual visit, OPTOS and CLARUS500 achieved quadratic weighted kappa values of 0.866 (95\% confidence interval, 0.842--0.878) and 0.852 (0.830--0.877), respectively. For incident ci-DME, CIRRUS5000 achieved the highest discrimination (AUC, 0.826; 0.770--0.878), whereas PLEX Elite9000 yielded the highest AUC point estimate for incident PDR (0.877; 0.807--0.950). Late fusion did not consistently outperform the strongest device-specific model. In secondary complete-case analyses, observed ci-DME incidence increased across quartiles of the image-derived risk score, reaching 19.7--30.4\% in the highest-risk quartile. AI models also achieved higher AUC point estimates than unassisted expert risk assessments for both complications, although these comparisons were exploratory.Retinal imaging acquired at a single routine-care visit therefore contains information associated with diabetic retinopathy severity and vision-threatening complications one year later. These findings support image-based short-term risk stratification, while external validation, calibration and prospective clinical utility assessment remain necessary before deployment.
No takes yet. Share an insight, caveat, or question.
DAHO et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: